WaveMan
WaveMan · Company
ZURA · Zura Bio Ltd
> Search tickers & screens ⌘K
LIVE
← All companies

ZURA Zura Bio (ZURA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001855644
Quote by TradingView
Form 144 · 4
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
59
13F, latest reported quarter

What the filings say about ZURA

Planned sales (Form 144), 90 days
$946.6K
4 notices

Zura Bio insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Zura Bio Ltd in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Access Industries Holdings LLC
BUY
2026-03-02 SECtraded 2026-02-26
2,000,000
$12.5M
-34.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 30.5% of the 6,552,725 shares held after it.
  • No other insider bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Access Industries Holdings LLC bought about $12.5M of ZURA on Feb 26, 2026, the largest insider purchase at the company on our record; 59 funds added in the latest 13F quarter.
Thiara Parvinder
Director
SELL
2024-11-27 SECtraded 2024-11-25
1,001,633
$2.7M
+40.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 11, 2024.
  • No other insider sold within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thiara Parvinder sold about $2.7M of ZURA on Nov 25, 2024; 59 funds added in the latest 13F quarter.
Thiara Parvinder
Director
SELL
2024-09-13 SECtraded 2024-09-11
3,800,000
$10.3M
+18.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 12, 2023.
  • The trade is 379.4% of the 1,001,633 shares held after it.
  • 1 other insider sold within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Thiara Parvinder sold about $10.3M of ZURA on Sep 11, 2024, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 59 funds added in the latest 13F quarter.
Sidhu Someit
Director
SELL
2024-09-06 SECtraded 2024-09-04
51,728
$200.2K
+18.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Apr 22, 2024.
  • The trade is 2.5% of the 2,085,418 shares held after it.
  • 1 other insider sold within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sidhu Someit sold about $200.2K of ZURA on Sep 4, 2024; 1 other insider sold within 30 days and 59 funds added in the latest 13F quarter.
Ploos van Amstel Arnout
Director
BUY
2024-05-23 SECtraded 2024-05-17
80,000
$496.0K
-22.2%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 80.0% of the 100,000 shares held after it.
  • 4 other insiders bought within 30 days.
  • 59 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ploos van Amstel Arnout bought about $496.0K of ZURA on May 17, 2024; 4 other insiders bought within 30 days and 59 funds added in the latest 13F quarter.
11 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 6 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
59 funds bought in last quarter
more than 51% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
20.8% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ZURA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+27.1%12M
+0%+37%+73%+110%2025-102025-122026-022026-042026-062026-082026-10 2026-02-26 · Access Industries Holdings LLC bought $12.5M2026-01-27 · Athanor Capital filed a 5%+ stake (15.7%)2026-01-27 · UGS Capital LLC filed a 5%+ stake (15.7%)2026-08-18 · SOMEIT SIDHU filed to sell $287.7K2026-08-17 · SOMEIT SIDHU filed to sell $151.3K2026-08-14 · SOMEIT SIDHU filed to sell $220.5K2026-08-13 · SOMEIT SIDHU filed to sell $287.0K
Insider buy13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ZURA: institutional holders (13F)

13F holdings, latest reported quarter
MONTANOVA CAPITAL, LLC
9,443,001 sh
$55.7M
Venrock Adviser, LLC
6,434,990 sh
$38.0M
MPM BIOIMPACT LLC
4,472,843 sh
$26.4M
GREAT POINT PARTNERS LLC
4,215,930 sh
$24.9M
JPMORGAN CHASE & CO
4,354,715 sh
$24.5M

Congress trades in ZURA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Athanor Capital
Activist 13D · 2026-01-27
15.7%
UGS Capital LLC
Activist 13D · 2026-01-27
15.7%

ZURA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SOMEIT SIDHU
Filed 2026-08-18
$287.7K
SOMEIT SIDHU
Filed 2026-08-17
$151.3K
SOMEIT SIDHU
Filed 2026-08-14
$220.5K
SOMEIT SIDHU
Filed 2026-08-13
$287.0K

ZURA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$382.2K position · as of 2026-05-31
0.2%
Small Cap Index Trust
$74.3K position · as of 2026-06-30
0.0%
Small Cap Index Fund
$179.8K position · as of 2026-06-30
0.0%
Nuveen Small Cap Blend Index Fund
$426.1K position · as of 2026-07-31
0.0%
Global X Russell 2000 ETF
$152.4K position · as of 2026-07-31
0.0%
PROFUND VP SMALL CAP
$932 position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
2 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows 59 funds added last quarter, $946.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ZURA financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$64.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-53.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-46.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-55.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-15.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$75.2M-$55.2M-$62.6M-$2.7M
Net income-$68.7M-$52.4M-$60.4M-$25.7M
EPS (diluted)-1.06-0.60-2.09n/a
Operating cash flow-$64.8M-$28.1M-$15.1M-$1.1M
Cash$109.4M$176.5M$99.8M$13.8K
SEC XBRL, fiscal years, as known on 2026-10-28

ZURA Stock Sonar score 3/7 axes

Find similar shapesCompare

ZURA ranks highest on institutional and government (51st percentile) and profitability (48th), and lowest on risk and compliance (14th), among Pharma & Biotech peers.

Profitability
48
Inputs
  • Return on equity-53.1% · 52 pct, sector of 545
  • Return on assets-46.2% · 47 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-55.2% · 46 pct, sector of 576
Institutional and government
51
Inputs
  • Funds adding, latest quarter59 · 51 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
14
Inputs
  • Short interest, % of float+20.8% · 14 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ZURA filings, in plain words

Are there planned insider sales of ZURA?

Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $946.6K of stock; the latest, by SOMEIT SIDHU, was filed 2026-08-18.

Read the full summary

Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $946.6K of stock. The latest 5% ownership filing is a 13D by Athanor Capital, filed 2026-01-27, for 15.7% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies